Effect of adding the topoisomerase I poison 7-ethyl-10-hydroxycamptothecin (SN-38) to 5-fluorouracil and folinic acid in HCT-8 cells: elevated dTTP pools and enhanced cytotoxicity
- PMID: 9771954
- DOI: 10.1007/s002800050835
Effect of adding the topoisomerase I poison 7-ethyl-10-hydroxycamptothecin (SN-38) to 5-fluorouracil and folinic acid in HCT-8 cells: elevated dTTP pools and enhanced cytotoxicity
Abstract
Purpose: To determine the effect of combined treatment with 7-ethyl-10-hydroxycamptothecin (SN-38, the active metabolite of irinotecan) and 5-fluorouracil/ folinic acid (5FU/FA) in vitro using HCT-8 human intestinal adenocarcinoma cells.
Methods: Cell survival was examined using colony forming assays. Cell cycle distribution before and after treatment was assessed by flow microfluorimetry. Levels of thymidylate synthase (TS) and topoisomerase I (topo I) in untreated and treated cells were determined by immunoblotting. Changes in deoxynucleotide pools were examined by high-performance liquid chromatography.
Results: Clonogenic assays revealed that colony formation was decreased by 50% after a 24-h exposure to 8+/-2 nM SN-38 or 12+/-3 microM 5FU, the latter being assayed in the presence of 2 microM FA. When treatment with 5FU/FA was followed by SN-38, the cytotoxicity was similar to that observed with 5FU/FA alone. In contrast, when HCT-8 cells were exposed to both agents simultaneously or to SN-38 followed by 5FU/FA, the cytotoxicity was greater than that of SN-38 or 5FU/FA treatment alone. Investigation of the mechanistic basis for this sequence dependence revealed that SN-38 treatment was associated with a dose- and time-dependent decrease in conversion of [5-3H]-2'-deoxyuridine to [3H]-H2O and thymidylate in intact cells. Immunoblotting failed to reveal any decrease in TS protein that could account for the decreased activity. High-performance liquid chromatography revealed that SN-38 treatment was associated with increased levels of the deoxynucleotide dTTP and decreased levels of dUTP. Flow microfluorimetry revealed that a 24-h treatment wit 10 nM SN-38 resulted in accumulation of HCT-8 cells in late S and G2 phases of the cell cycle, with a further increase in the G2 fraction during the 24 h after SN-38 removal.
Conclusions: These observations are consistent with a model in which SN-38 sequentially induces diminished DNA synthesis, elevated dTTP pools, inhibition of dUMP synthesis and enhanced toxicity of 5FU/FA. Accordingly, sequencing of irinotecan and 5FU/FA might be important in combining these agents into an effective treatment for colorectal cancer.
Similar articles
-
Determinants of cytotoxicity with prolonged exposure to fluorouracil in human colon cancer cells.Oncol Res. 1997;9(2):77-88. Oncol Res. 1997. PMID: 9167189
-
Combination of 5-fluorouracil and irinotecan on modulation of thymidylate synthase and topoisomerase I expression and cell cycle regulation in human colon cancer LoVo cells: clinical relevance.Clin Colorectal Cancer. 2002 Nov;2(3):182-8. doi: 10.3816/CCC.2002.n.023. Clin Colorectal Cancer. 2002. PMID: 12482336
-
The HER tyrosine kinase inhibitor CI1033 enhances cytotoxicity of 7-ethyl-10-hydroxycamptothecin and topotecan by inhibiting breast cancer resistance protein-mediated drug efflux.Cancer Res. 2001 Jan 15;61(2):739-48. Cancer Res. 2001. PMID: 11212277
-
Induction of thymidylate synthase as a 5-fluorouracil resistance mechanism.Biochim Biophys Acta. 2002 Jul 18;1587(2-3):194-205. doi: 10.1016/s0925-4439(02)00082-0. Biochim Biophys Acta. 2002. PMID: 12084461 Review.
-
The role of topoisomerase I inhibitor in cisplatin-resistant ovarian cancer.Hum Cell. 2001 Sep;14(3):237-43. Hum Cell. 2001. PMID: 11774743 Review.
Cited by
-
The role of FOLFIRINOX in metastatic pancreatic cancer: a meta-analysis.World J Surg Oncol. 2021 Jun 21;19(1):182. doi: 10.1186/s12957-021-02291-6. World J Surg Oncol. 2021. PMID: 34154596 Free PMC article. Review.
-
The present and future of systemic and microenvironment-targeted therapy for pancreatic adenocarcinoma.Ann Pancreat Cancer. 2020 May;3:3. doi: 10.21037/apc-2020-pda-05. Epub 2020 May 20. Ann Pancreat Cancer. 2020. PMID: 33294843 Free PMC article.
-
Phase I/II study of a 3-week cycle of irinotecan and S-1 in patients with advanced colorectal cancer.Cancer Sci. 2010 Dec;101(12):2591-5. doi: 10.1111/j.1349-7006.2010.01728.x. Epub 2010 Sep 24. Cancer Sci. 2010. PMID: 21077997 Free PMC article. Clinical Trial.
-
Phase I Dose-Escalation Trial of an Innovative Chemotherapy Regimen Combining a Fractionated Dose of Irinotecan Plus Bevacizumab, Oxaliplatin, 5-Fluorouracil, and Folinic Acid (bFOLFIRINOX-3) in Chemorefractory Metastatic Colorectal Cancer.Cancers (Basel). 2021 Oct 30;13(21):5472. doi: 10.3390/cancers13215472. Cancers (Basel). 2021. PMID: 34771635 Free PMC article.
-
FOLFIRINOX-3 plus bevacizumab (bFOLFIRINOX3) in chemo-refractory metastatic colorectal cancer: a multicenter phase II trial.Future Oncol. 2025 Mar;21(6):699-706. doi: 10.1080/14796694.2025.2461446. Epub 2025 Feb 6. Future Oncol. 2025. PMID: 39913183 Free PMC article. Clinical Trial.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical